Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

Stephanie L. Graff, MD
Published: Monday, Jul 23, 2018



Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

At the 2018 ASCO Annual Meeting, Aditya Bardia, MD, MPH, of Massachusetts General Hospital, presented updated results on the use of sacituzumab govitecan in the metastatic hormone-receptor (HR)-positive setting. Bardia also presented updated results in the triple-negative space at the 2017 San Antonio Breast Cancer Symposium.

Sacituzumab govitecan has shown tremendous response rates in both groups, says Graff. Graff notes that the data presented by Bardia at the 2018 ASCO Annual Meeting in HR-positive patients are equally as compelling as the data seen in triple-negative breast cancer (TNBC). The maker of the antibody-drug conjugate is seeking an accelerated approval by the FDA. The phase III trial in metastatic TNBC is currently accruing.

The compound is likely to become a breakthrough drug, says Graff, and may be tool for physicians to use across multiple breast cancer subtypes in the clinic very soon.


Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

At the 2018 ASCO Annual Meeting, Aditya Bardia, MD, MPH, of Massachusetts General Hospital, presented updated results on the use of sacituzumab govitecan in the metastatic hormone-receptor (HR)-positive setting. Bardia also presented updated results in the triple-negative space at the 2017 San Antonio Breast Cancer Symposium.

Sacituzumab govitecan has shown tremendous response rates in both groups, says Graff. Graff notes that the data presented by Bardia at the 2018 ASCO Annual Meeting in HR-positive patients are equally as compelling as the data seen in triple-negative breast cancer (TNBC). The maker of the antibody-drug conjugate is seeking an accelerated approval by the FDA. The phase III trial in metastatic TNBC is currently accruing.

The compound is likely to become a breakthrough drug, says Graff, and may be tool for physicians to use across multiple breast cancer subtypes in the clinic very soon.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x